DEFICIENCIES IN MITOCHONDRIAL fatty acid ␤-oxidation (FAO) enzymes have been implicated in cardiomyopathy, arrhythmias, sudden death, nonketotic hypoglycemia, heart and liver lipidosis, encephalopathy, and skeletal myopathy (21, 41, 46) . Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a FAO defect that usually presents with episodes of metabolic crisis and death in children (15) and causes ventricular tachycardia (VT) in almost 50% of the presenting cases (34) . Most cases of sudden death occur in the first year of life (15) . There has been little research on the mechanisms leading to cardiac dysfunction and ventricular arrhythmias in VLCAD deficiency. We developed a mouse model of VLCAD deficiency and characterized the cardiac phenotype in these mice, revealing lipid accumulation and mitochondrial proliferation in myocytes and inducible polymorphic VT, which is exacerbated by adrenergic stimulation (14) .
We have hypothesized that altered intracellular Ca 2ϩ homeostasis resulting from dysregulation of Ca 2ϩ -regulated proteins may be at the basis of the VT in VLCAD deficiency. Our hypothesis originated from partial cDNA microarray data in which we found that levels of several of the Ca 2ϩ -related proteins were quantitatively different in mouse hearts deficient in VLCAD at birth and 2 mo after birth. At a cellular level and in several metabolic pathways, Ca 2ϩ is an important messenger that serves a vital role in cell signaling. In muscle, Ca 2ϩ influx though sarcolemmal ion channels triggers the mobilization of Ca 2ϩ from intracellular stores (Ca 2ϩ -induced Ca 2ϩ release), thereby leading to the contraction of the heart (systole; see Refs. 6 and 7). Abnormalities of intracellular Ca 2ϩ handling are hypothesized to induce diastolic depolarization that can trigger ventricular arrhythmias (29, 30, 32, 33) . Abnormalities in Ca 2ϩ handling are also found in patients with familial catecholaminergic polymorphic ventricular tachycardia (CPVT), a genetic arrhythmia syndrome characterized by polymorphic VT associated with adrenergic stimulation. Intracellular Ca 2ϩ homeostasis is modulated by intracellular Ca 2ϩ release channels (ryanodine receptors, RyRs), which are widely distributed in tissues: RyR1 in skeletal muscle, RyR2 in cardiac muscle, and RyR3 in a variety of tissues but in minuscule amounts. Mutations in the cardiac ryanodine receptor (RyR2) gene are known to cause both CPVT, also termed familial polymorphic ventricular tachycardia (FPVT) or bidirectional VT (28, 29, 39, 48) , and arrhythmogenic right ventricular dysplasia (40, 49) . These mutations cause a "gain-of-function" or increased Ca 2ϩ leak from the sarcoplasmic reticulum (SR; see Ref. 33) .
Given that VLCAD-deficient babies present with severe forms of ventricular dysfunction and arrhythmias (34) , and that our mouse model of VLCAD deficiency has easily inducible ventricular arrhythmias, we investigated whether defective cardiomyocyte Ca 2ϩ handling plays a role in the development of cardiomyopathy in the VLCAD-deficient mouse. In this study, we used our mouse model of VLCAD deficiency (VLCAD Ϫ/Ϫ ; see Ref. 14) to show a novel role for mitochondrial FAO defects in the regulation of Ca 2ϩ signaling in heart. We assessed functional changes of intracellular Ca 2ϩ homeostasis and dynamics in hearts from VLCAD ϩ/ϩ and VLCAD Ϫ/Ϫ mice. Our results provide new insights into Ca 2ϩ handling in the settings of VLCAD deficiency in mice and perhaps in humans.
MATERIALS AND METHODS

VLCAD
Ϫ/Ϫ mice. All animals in this study were cared for according to the Institutional Animal Care and Use Committee at Vanderbilt University. Mice were generated and genotyped as previously described (13, 14) . Mice of 2-3 mo of age were included in these studies. Intracardiac electrophysiological studies were performed in 12 VLCAD Ϫ/Ϫ and 16 VLCAD ϩ/ϩ male mice. Subcellular fractions were performed in 24 VLCAD Ϫ/Ϫ mice (16 males, 8 females) and 12 VLCAD ϩ/ϩ mice (8 males, 4 females). Upon death or at autopsy, whole heart ventricles and skeletal muscle (slow and fast twitch) were harvested for total protein analysis.
Intracardiac electrophysiology studies. Mice were anesthetized with pentobarbital sodium (0.070 mg/g ip). A surface electrocardiogram (ECG; lead I) was obtained by placement of subcutaneous 27-gauge needles in each foreleg. ECG channels were amplified (0.1 mV/cm) and filtered between 0.05 and 400 Hz. Under an operating microscope, a cut down of the right internal jugular vein was performed, and an octapolar 2-Fr electrode catheter (CIBer cath; NuMED) was placed in the right atrium and right ventricle, guided by electrogram tracing to verify placement.
Bipolar electrogram recordings were obtained from the right atrium, right ventricle, and His positions. Signals were amplified and filtered between 40 and 400 Hz. Bipolar pacing was performed using a programmable stimulator (Medtronic 2356) modified by the manufacturer to deliver coupling intervals as short as 10 ms. Pacing threshold (in mA) was determined for each pacing site, and stimulation was performed for 1.0-to 2.0-ms pulse width at two times the diastolic capture threshold. Electrophysiological intervals (RR, PR, QRS, QT, AH, HV, and AV) were measured in standard fashion. Standard clinical electrophysiological pacing protocols were used to determine all basic electrophysiological parameters. The AV-HisPurkinje conduction properties were assessed through rapid atrial pacing at rates up to 1,000 beats/min. The Wenckebach cycle length, defined as the longest atrial paced cycle length that failed to conduct 1:1 to the ventricle, was determined. Programmed right atrial stimulation was performed to determine AV node effective refractory period, defined as the longest premature stimulus that failed to conduct to the ventricle. Ventricular effective refractory period was determined at three drive cycle lengths. Single, double, and triple extra stimuli were delivered at three drive cycle lengths to determine inducibility of VT. The duration and cycle length of induced tachycardias were recorded. After baseline measurements were completed, isoproterenol was administered (100 g ip), and the protocols were repeated to assess the effects on conduction and refractoriness.
Preparation and characterization of subcellular fractions from mouse hearts. Subcellular fractionation was performed by the method described by Chamberlain and Fleischer (10) . Cardiac microsomal fractions enriched in SR were analyzed by SDS-PAGE (6% resolving gel), and the protein profile was visualized with Coomassie blue staining. For Western blot analysis of RyR2 after SDS-PAGE, proteins were transferred to an Immobilon-P membrane in blot transfer buffer (in mM: 48 Tris, 39 glycine, and 1.3 SDS, pH 9.2) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad). The vacant binding sites on the membrane were blocked by incubating the membrane in wash buffer (10 mM Tris ⅐ Cl, pH 8.0, 0.55 M NaCl, and 0.05% Tween 20) containing 5% nonfat dry milk protein for 1 h. The Immobilon-P membrane was probed with a RyR2-specific antibody (1:1,000) in blocking buffer for 1 h, washed three times with wash buffer, and then incubated with secondary antibody goat antirabbit IgG conjugated to peroxidase (Sigma) in blocking buffer. The membrane was again washed three times with wash buffer, and immune complexes were detected by the enhanced chemiluminescence Western blotting analysis system (Amersham Pharmacia Biotech). RyR1, -2, and -3 specific antibodies were obtained from the Fleischer laboratory, Vanderbilt University (26) (Sigma) . Free ligand was separated from the bound ligand by sedimenting the microsomes in a Beckman TL-100.1 rotor at 95,000 revolutions/min for 15 min at 4°C. The supernatants were removed by aspiration, the pellets were rinsed two times and resuspended in 200 l water, and the radioactivity was measured in 5 ml of Cytoscint (ICN, Cleveland, OH) in a Beckman LS 5000TD scintillation counter. Upon completion of the experiment, radioactivity was measured and expressed as picomoles per milligram of protein. Binding was calculated based on the formula (total cpm Ϫ nonspecific cpm)/(cpm/pmol ϫ mg protein) (26) .
Preparation of ventricular myocytes. Mice were anesthetized by intraperitoneal injection of Avertin solution (5 mg Avertin/10 g body wt, T48402; Sigma-Aldrich) containing heparin (3 mg/10 ml, H9399; Sigma-Aldrich). The heart was rapidly excised and placed in ice-cold Ca 2ϩ -free and glucose-free HEPES-buffered Tyrode solution. The Tyrode solution contained (in mM) 140 Na ϩ , 4.5 K ϩ , 0.5 Mg 2ϩ , 150 Cl Ϫ , 0.4 H2PO 4 Ϫ , 10 HCO 3 Ϫ , and 10 HEPES. The pH of all solutions was adjusted to 7.4 using NaOH. The aorta was cannulated, and the heart was perfused with Tyrode solution at room temperature for 10 min to stop contractions. The perfusion was switched to Tyrode solution containing 10 M Ca 2ϩ , 178 U/ml collagenase (CLS2; Worthington Biochemical), and 0.64 U/ml protease (P5147; SigmaAldrich) for 12 min at 37°C. Tissues from the atria and aorta were discarded. Remaining ventricular tissue was coarsely minced and placed in Tyrode solution containing the C-16 fatty acid energy substrate palmitate (10 M, palmitic acid P0500; Sigma-Aldrich) and 0.5 mM Ca 2ϩ . Myocytes were dissociated by gentle agitation and used within 3 h after isolation.
Measurement of intracellular Ca 2ϩ transients. Dissociated cardiomyocytes were loaded for 15 min with the acetoxymethyl ester forms of the Ca 2ϩ -sensitive fluorescence indicators indo 1 (20 M I1203; Invitrogen) or fura 2 (5 M, F1221; Invitrogen). Cells were then centrifuged for 10 min at 27 g and resuspended in Tyrode solution containing 1.0 mM Ca 2ϩ . Ca 2ϩ transients were measured in Tyrode solution containing 1.0 mM Ca 2ϩ and 10 M palmitate at 37°C, supplemented with an insulin-transferrin-selenium mixture (100ϫ medium supplement, 41400, consisting of 10 g/ml insulin, 5.5 g/ml transferrin, 6.7 ng/ml sodium selenite; GIBCO-Invitrogen) to improve the performance of the isolated cells at the high stimulation frequencies (42) . Myocytes were field stimulated at 600 and 250 beats/min via two parallel platinum wires. Fluorescence measurements were carried out using an inverted microscope (Axiovert 200; Carl Zeiss) equipped with a ϫ63, 1.4 NA oil immersion lens (Plan Apochromat; Carl Zeiss). For the fura 1 measurements, the excitation wavelength was rapidly switched between 340 Ϯ 10 and 380 Ϯ 10 nm at a rate of ϳ200 ratios/s by using a monochromator (Optoscan; Cairn Research). For the indo 1 measurements, the excitation wavelength was fixed at 365 Ϯ 15 nm. The excitation light was reflected on the cells by a dichroic mirror (415DCLP for fura 1 and 390DRLP for indo 1; Omega Optical). Fura 2 fluorescence emission was recorded at a wavelength of 510 nm.
With the use of a bandpass emission filter (510WB40; Omega Optical), indo 1 fluorescence was split into two components by a second dichroic mirror (450DCLP; Omega Optical), and each component passed through a 495-nm (495DF20; Omega Optical) or a 405-nm bandpass filter (405DF43; Omega Optical). The light was collected by 1-mm-diameter optical fibers mounted behind the emission filters imaging a ϳ16-m-diameter spot on the cell. Fluorescence emission was registered by photomultiplier modules (H6780; Hamamatsu) and amplified by a custom-built low-noise direct currentcoupled amplifier. The signals were digitized at a sampling rate of 20 kHz by an analog/digital (A/D) converter board (PCI-6071E; National Instruments) in a conventional personal computer (PC).
Fluorescence calibration. Fluorescence emission ratios were converted to intracellular Ca 2ϩ concentrations ([Ca 2ϩ ]i) according to the equation (20) 
, using published in vivo dissociation constants for fura 1 and indo 1 of 371 (23) and 844 (3) nM, respectively. R values in the previous equation were calculated as ratios of 405/495 nm fluorescence emission (indo 1) and 340/380 nm excitation at 510 nm emission (fura 2). ␤ Values were calculated as ratios of Ca 2ϩ -free/saturated indicator at excitation/emission wavelengths of 365/495 nm (indo 1) and 380/510 nm (fura 2). R min and Rmax were determined in vivo. Cells were loaded with Ca 2ϩ dye and exposed to 10 mM caffeine two times to empty the SR. For R min determination, cells were superfused with Ca 2ϩ -free Tyrode solution containing 5 mM EGTA and 10 M of the nonfluorescent ionophore bromo-A-23187 (B7272; Sigma-Aldrich). Measurements were taken after the fluorescence reached stable values at both wavelengths. For R max determination, extracellular Ca 2ϩ concentration was gradually increased to 10 mM in the presence of the metabolic inhibitor cyanide p-(trifluoromethoxy)-phenylhydrazone (3 M, C2920; Sigma-Aldrich) to avoid hypercontracture. The Ca 2ϩ ionophore was present throughout the calibration procedure.
Sarcomere contraction measurements. Sarcomere contraction was measured in single cardiac myocytes using a commercial contractility measurement system (Ionoptix) consisting of a 240-frames/s CCD camera (MYO100; Ionoptix) connected to a side port of the microscope, a frame grabber PC card (FRGRAB; Ionoptix), and an A/D converter (DSI200; Ionoptix) to record the stimulus. Data were acquired using the IonWizard software. Cells were field stimulated at 240 beats/min to obtain 60 data points for each contraction at the maximum acquisition rate of 240 frames/s.
Electrophysiology. L-type Ca 2ϩ current (ICa) was recorded in the whole cell mode voltage-clamp configuration according to previously published methods (22) . Briefly, pipettes (2-3 M⍀) contained (in mM) 120 Cs ϩ , 3 Ca 2ϩ , 126 Cl Ϫ , 1 MgATP, 1 NaGTP, 5 phosphocreatine, 10 HEPES, and 10 EGTA (1). The pH was adjusted to 7.2 with CsOH. The bath solution contained Tyrode solution as described above with 10 M palmitic acid and 1.8 mM Ca 2ϩ . The holding potential was Ϫ90 mV. I Ca was measured during 500-ms test pulses at potentials ranging from Ϫ40 to ϩ40 mV following a 50-ms pulse at Ϫ50 mV to inactivate Na ϩ current (12, 31 
RESULTS
Polymorphic and bidirectional VT in the VLCAD
Ϫ/Ϫ mice. VLCAD Ϫ/Ϫ mice, although viable, demonstrated easily inducible VT in the absence of physiological stress. There was no difference in heart rate, PR interval, Wenckebach cycle length (defined as the longest atrial paced cycle length with failure of 1:1 conduction to the ventricle), or ventricular effective refractory period (defined as the longest coupling interval that fails to capture the ventricle) between VLCAD ϩ/ϩ and VLCAD
mice. With the use of programmed ventricular stimulation, VT could be induced in 6/12 (50%) of VLCAD Ϫ/Ϫ mice compared with 2/16 (12%) wild-type mice. VT in the VLCAD Ϫ/Ϫ mice was consistently polymorphic. VT inducibility was increased in the VLCAD Ϫ/Ϫ mice to 10/12 (83%) when isoproterenol was used. VT with the typical bidirectional morphology with isoproterenol infusion was observed in 1 out of 10 mice (Fig. 1) . Isoproterenol did not increase arrhythmia inducibility in wild-type mice.
Increased expression of RyR2 isoform in mouse hearts and augmented ryanodine binding in microsomes of VLCAD
Ϫ/Ϫ mice. Given our microarray results suggesting changes in Ca 2ϩ -related genes and other reports showing a possible link between polymorphic/bidirectional VT and excessive RyR2 activity (32, 33, 39) , we first tested whether RyRs were differently expressed in the VLCAD Ϫ/Ϫ mice. Western blot analyses using isoform-specific antibodies showed a 3.04 Ϯ 0.8-fold increase in RyR2 expression in VLCAD Ϫ/Ϫ mice compared with VLCAD ϩ/ϩ hearts (Fig. 2, A-C) . We also found that in VLCAD Ϫ/Ϫ mice RyR1 levels were increased 3.3 Ϯ 0.1-fold in skeletal muscle, and RyR3 levels were increased 2. Fig. 3 . We confirmed our results in two series of independent experiments using two different fluorescence dyes with different Ca 2ϩ -binding affinities, and at two different pacing rates. Because the physiological heart rate in a mouse is on the order of 600 -700 beats/min, we initially measured Ca 2ϩ transients at 10 Hz (Fig. 3A) . Under these conditions, Ca 2ϩ transients were significantly larger in VLCAD Ϫ/Ϫ cardiac myocytes compared with VLCAD ϩ/ϩ control cells. However, rapid pacing itself increased diastolic Ca 2ϩ concentration in all cells (Fig 3C) . The increased binding of Ca 2ϩ to intracellular ligands that occurs when diastolic Ca 2ϩ concentration is high may by itself increase free Ca 2ϩ concentration and the amplitude of the Ca 2ϩ transient. Therefore, we performed measurements at 4 Hz to achieve a lower baseline Ca 2ϩ concentration and to reduce mitochondrial Ca 2ϩ loading. Although diastolic fluorescence was significantly lower in VLCAD ϩ/ϩ control myocytes at 4 Hz, i.e., 159 Ϯ 40 nM (Fig. 3B) , it was still threefold higher in VLCAD Ϫ/Ϫ cardiac myocytes (Fig. 3, B and C) . These data were consistent with the fluorescence data at 10 Hz. The amplitude of Ca 2ϩ transient was significantly increased in VLCAD Ϫ/Ϫ cells at 4 Hz (Fig. 3, B and D) , and this increase was even more pronounced at the lower pacing rate (Fig. 3D) .
To further characterize Ca 2ϩ transients in VLCAD Ϫ/Ϫ cardiac myocytes, we subsequently calculated the maximum time derivatives of Ca 2ϩ transient upstroke and decay. We found that maximum slopes of the transients were significantly increased in VLCAD Ϫ/Ϫ myocytes (Fig. 4A) , although times of fluorescence rise and fall were about the same (Fig. 4B) . One of our hypotheses was that the increase in Ca 2ϩ transient amplitude was the result of an increase in SR Ca 2ϩ content. We tested this hypothesis by measuring the integrated NCX current after fast application of caffeine (Fig. 4C) cardiomyocytes. We also measured sarcomere contraction and relaxation to test whether changes in time course and amplitude of Ca 2ϩ transients had any impact on cardiomyocyte contractility. We found that sarcomere contraction was significantly hastened in VLCAD Ϫ/Ϫ cardiomyocytes compared with VLCAD ϩ/ϩ control cells (Fig. 5A) . Duration of contraction transient (as measured at 50% of the maximum contraction) was shortened by ϳ30% in VLCAD Ϫ/Ϫ cells (Fig. 5B) , which was consistent with an increase in contraction velocity. Maximum contraction velocity was increased by 28% (Fig. 5D) , and time-to-maximum was decreased by 25% (Fig. 5E ) in VLCAD Ϫ/Ϫ cardiomyocytes. There was, however, no difference in sarcomere relaxation (Fig. 5, D and E) . Interestingly, amplitude of sarcomere contraction was the same in VLCAD Ϫ/Ϫ (85 Ϯ 15 nm) and VLCAD ϩ/ϩ (96 Ϯ 10 nm) cardiac myocytes (Fig. 5C ). There was no difference in diastolic sarcomere lengths in VLCAD Ϫ/Ϫ (1.749 Ϯ 0.003 m) compared with VLCAD channel, given that contribution from NCX reverse mode is believed to be small (ϳ7%) in mouse and rat ventricles (5, 6). We found that both amplitude and time course of I Ca were not changed under voltage-clamp conditions in VLCAD Ϫ/Ϫ cardiac myocytes using a test potential of 0 mV (Fig. 6A) . The slow and the fast time constants of I Ca inactivation were the same, with 92 Ϯ 6 and 12.0 Ϯ 3 ms in VLCAD Ϫ/Ϫ and 92 Ϯ 5 and 12 Ϯ 3 ms in VLCAD ϩ/ϩ cardiomyocytes as indicated by the recovery period of the current traces in Fig. 6A . We also measured the current-voltage relationship of mean peak I Ca and found no differences between VLCAD Ϫ/Ϫ and VLCAD ϩ/ϩ cells (Fig. 6B) -related proteins was also changed in our model. Western blot analyses showed a sevenfold increase in calsequestrin levels (Fig. 7, A and B) . Protein levels of SERCA2a were not changed (Fig. 7, A and D) . The monomeric form of phospholamban was unchanged although the pentameric form of phospholamban was increased 6.0 Ϯ 0.9-fold in the VLCAD Ϫ/Ϫ cells compared with control (Fig. 7D) .
DISCUSSION
VLCAD deficiency in mice leads to polymorphic and bidirectional VT.
Children with mitochondrial VLCAD deficiency present with cardiomyopathy, ventricular arrhythmias, and sudden unexpected death (34, 46) . Deficiencies in several of the mitochondrial FAO enzymes are also associated with arrhythmias and sudden unexpected death in humans, but the mechanism is unclear. In this article, we demonstrated that VLCAD deficiency in mice leads to catecholamine-sensitive polymorphic VT and in one case to bidirectional VT. Our results show that VLCAD deficiency in mice leads to alterations in intracellular Ca 2ϩ homeostasis, which might mimic electrophysiological aspects of RyR2 and/or calsequestrin mutations in humans (17) . RyR2 and/ or calsequestrin mutations in humans lead to FPVT/CPVT, although many patients with FPVT/CPVT do not have identifiable mutations in RyR2 or calsequestrin (38) . A mutation in ankyrin B was found in a patient with a phenotype similar to catecholaminergic VT (37 ] i following a release. As a consequence, we tested whether the increase in transient amplitude was the result of less systolic Ca 2ϩ buffering in the VLCAD Ϫ/Ϫ cardiomyocytes. We estimated the increase in free Ca 2ϩ concentration (i.e., the increase in Ca ] i using a lumped K d of 0.63 M for all cytosolic Ca 2ϩ buffers and a total buffer capacity of the cytosol equal to 162 M. Under these assumptions, we found that the increase in diastolic [Ca 2ϩ ] i in VLCAD Ϫ/Ϫ cardiac myocytes could account for nearly 80% of the increase in Ca 2ϩ transients in these cells when stimulated at 10 Hz (Fig. 3A) .
The interpretation of our high baseline Ca 2ϩ fluorescence levels in the VLCAD Ϫ/Ϫ cardiomyocytes needs to also take into account the contribution of mitochondrial Ca 2ϩ loading. Mitochondrial Ca 2ϩ has been shown to be significant when resting Ca 2ϩ concentration exceeds 300 -500 nM, as demonstrated by Zhou et al. (53) . Mitochondrial dye loading cannot be avoided using the ester form of indo 1. This is why we subsequently performed Ca 2ϩ fluorescence measurements at a lower stimulation frequency of 4 Hz using fura 2 (Fig. 3B) . The ester form of fura 2 accumulates less in intracellular compartments (9) . The lower pacing rate using fura 2 significantly reduced diastolic Ca 2ϩ concentration in wild-type control cardiac myocytes to a value of Ͻ200 nM (Fig. 3, B and C) , which compares well with literature data (8, 18) . However, under the slow pacing condition, amplitude of Ca 2ϩ transients was higher in all myocytes, which may be a result of an increased uptake of Ca 2ϩ in the SR (negative staircase effect; see Refs. 16 and 47).
More importantly, our fura 2 experiments continued to show a marked increase in baseline fluorescence in VLCAD Ϫ/Ϫ cardiac myocytes, which translated to a more than threefold increase in diastolic Ca 2ϩ concentration compared with VLCAD ϩ/ϩ control cells (Fig. 3, B and C) . Because of reduced buffering in VLCAD Ϫ/Ϫ myocytes is expected to be higher at the slow compared with the fast pacing rate because more intracellular Ca 2ϩ buffer binding sides should be available when diastolic Ca 2ϩ concentration is lower. We estimated that, at the slower pacing rate of 4 Hz, the change in Ca 2ϩ buffering may account for ϳ60% of the increase in transient amplitude. The observed increase in transient amplitude was even higher at the lower pacing rate. Likely, at these lower diastolic Ca 2ϩ levels, the effect of VLCAD deficiency on the amplitude of Ca 2ϩ transient was more pronounced because of the larger Ca 2ϩ concentration gradient between the SR and the cytosol (negative staircase). Interestingly, the normalized integrated NCX current was increased by 48% after rapid caffeine application in VLCAD Ϫ/Ϫ cells (Fig. 4C) . The increased caffeineinduced Ca 2ϩ release together with the increased expression of SR Ca 2ϩ -binding protein calsequestrin (Fig. 7, A and B (Fig. 5, A and D) , which was consistent with an enhanced Ca 2ϩ transient in these cells (Figs. 3 and 4) . Faster contraction was evident in a shorter contraction transient (Fig.  5B) , a larger time derivative of the upstroke (Fig. 5D) , and a shorter time-to-minimum sarcomere length (Fig. 5E) . Surprisingly, the mean contraction amplitude was not changed in the VLCAD Ϫ/Ϫ cardiomyocytes ( Fig. 5C ; P ϭ 0.53). The observed increase in diastolic Ca 2ϩ in VLCAD Ϫ/Ϫ cardiac myocytes did not translate into a decreased diastolic sarcomere length (Fig. 5A ). It might be speculated that myofilament response to cytosolic Ca 2ϩ was altered in VLCAD Ϫ/Ϫ cardiac myocytes, but a direct measurement of myofilament Ca 2ϩ sensitivity in the VLCAD cardiomyocytes would be required to test this hypothesis.
VLCAD deficiency alters expression of Ca 2ϩ regulatory proteins. We have previously shown that VLCAD Ϫ/Ϫ mice have a number of biochemical changes suggestive of complex alteration in lipid metabolism and lipid transport that are present in the heart at birth, whereas ultrastructural abnormalities develop postnatally (14) . Although these changes may be part of the compensatory molecular events that occur in the absence of VLCAD, it is also conceivable that the biochemical changes that we presently report are directly related to the disease phenotype. Here, we report changes in the expression of several Ca 2ϩ regulatory proteins in heart. These findings have not been previously reported in VLCAD deficiency or in other models of mitochondrial FAO defects. We found that all RyR isoforms (i.e., RyR1 in skeletal muscle, RyR2 in heart, and RyR3 in brain) were upregulated. [ 3 H]ryanodine binding was also increased in VLCAD Ϫ/Ϫ microsomes compared with microsomes from control mouse hearts. In our model, we also found that the pentameric form of phospholamban was upregulated in VLCAD Ϫ/Ϫ myocytes (Fig. 7D) . Although several studies show that phospholamban asserts its inhibitory function by binding to SERCA in its monomeric form (2, 24, 25) there is some evidence that the pentameric form of phospholamban may directly interact with SERCA2a, causing a decrease in the affinity of the pump for Ca 2ϩ (45, 52) . However, the mechanism of this interaction is not fully understood. Pentameric phospholamban has been proposed to form an ion pore in SR Altogether, the present work supports the concept of a previously unrecognized connection between a clinically important metabolic defect, upregulation of SR Ca 2ϩ stores and release proteins, enhanced sarcomere contraction, and increased susceptibility to adrenergically mediated arrhythmias. Our current hypothesis is that changes in the regulation of [Ca 2ϩ ] i are likely directly related to the cardiac phenotype of VLCAD deficiency and may serve as an added substrate for VT in the VLCAD Ϫ/Ϫ mouse. Enhanced SR Ca 2ϩ load may increase spontaneous Ca 2ϩ release, which is a hypothesized molecular mechanism of polymorphic and bidirectional VT. Whether changes in RyR, phospholamban, or calsequestrin were true contributors to the observed ventricular arrhythmias is not known. Our findings, however, support a mechanism in which VLCAD deficiency, perhaps through decreased ATP production, leads to alteration in intracellular Ca 2ϩ homeostasis and elevated SR Ca 2ϩ load. These changes have the potential to alter excitation-contraction coupling, leading to cardiac rhythm abnormalities. In the future, we will need to assess whether there are inherent or preexisting changes in RyR2, phospholamban, and/or calsequestrin that lead to abnormal Ca 2ϩ handling or whether the accumulation of toxic metabolites resulting from VLCAD deficiency causes the observed changes in Ca 2ϩ homeostasis. Given that these Ca 2ϩ changes were consistently observed in the VLCAD Ϫ/Ϫ mice, abnormalities in intracellular Ca 2ϩ handling may represent a plausible cellular mechanism for ventricular arrhythmia in VLCAD deficiency and/or several of the FAO enzyme defects.
There are several limitations to our study. Ca 2ϩ fluorescence amplitude may differ from SR Ca 2ϩ release because sarcolem- mal ion currents were not blocked in our experiments. Although in mouse ventricles most of the Ca 2ϩ that enters the cytosol during systole is released from the SR (ϳ92%, compared with ϳ70% in humans), other ion currents (such as the reverse-mode NCX) might have partly contributed to the increase in systolic free Ca 2ϩ concentration in VLCAD Ϫ/Ϫ myocytes (5, 6). These currents were not individually measured. Furthermore, mitochondrial Ca 2ϩ loading can be expected to occur in VLCAD Ϫ/Ϫ myocytes even when diastolic Ca 2ϩ concentration is low (19, 53) . Because both indo 1 and fura 2 are known to accumulate in noncytoplasmic compartments (9), fluorescence originating from Ca 2ϩ trapped in the mitochondria may superimpose the cytosolic component of Ca 2ϩ transient. Therefore, it is important to note that quantitative changes in maximum time derivatives of total Ca 2ϩ fluorescence are only suggestive of changes in SR Ca 2ϩ release and uptake fluxes. Additional experiments would be required to determine the exact contribution of Ca 2ϩ fluxes resulting from noncytoplasmic compartments, the sarcolemma, and the mitochondria. Notwithstanding these limitations, our findings remain true: Ca 2ϩ homeostasis is altered in the VLCAD Ϫ/Ϫ mouse heart, which is a possible underlying mechanism for polymorphic VT in mice and perhaps in humans. In summary, in this research report, we have provided evidence that VLCAD deficiency in mice is associated with polymorphic and bidirectional VT, elevated levels of critical Ca 2ϩ regulatory proteins with elevated diastolic and systolic Ca 2ϩ , and elevated SR Ca 2ϩ stores. Findings in this mouse model raise the following critical questions. 1) Does VLCAD deficiency in humans contribute to a subset of cardiac arrhythmias that resembles defects in Ca 2ϩ release channels of the heart? 2) Do our findings represent a molecular mechanism for arrhythmias in other models of FAO deficiency? Long-term follow-up of patients with VLCAD deficiency has been limited by the fact that most of the cases present in childhood with sudden death as presenting sign. Patients who survive into adulthood may have no symptoms and structurally normal hearts (without cardiac hypertrophy or dilation). Our data, however, raise the possibility that these patients may still be at risk for VT specifically related to changes in Ca 2ϩ handling in the absence of cardiac hypertrophy or dilation. Our results also suggest that VLCAD deficiency in humans may contribute to a subset of cases with FPVT/CPVT and point to a molecular mechanism for arrhythmias in other cases of FAO deficiency. 
